Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417883 | 0.84 | MCL1 (0.38) | MCL1CASP1MAPTALDH1A1DPP4 | |
| SCHEMBL14673211 | 0.83 | MCL1 (0.37) | MCL1CASP1MAPTCHRNB2CHRNA4 | |
| SCHEMBL8015541 | 0.77 | MCL1 (0.39) | MCL1 | |
| SCHEMBL9653268 | 0.77 | — | — | |
| SCHEMBL14417885 | 0.76 | MCL1 (0.53) | MCL1MAPTALDH1A1 | |
| SCHEMBL3263776 | 0.76 | — | — | |
| SCHEMBL30740976 | 0.75 | ALDH1A1 (0.39) | MCL1CASP1ALDH1A1DPP4 | |
| SCHEMBL30740904 | 0.74 | MVD (0.40) | MCL1CASP1DPP4 | |
| SCHEMBL3023839 | 0.74 | CNR1 (0.50) | CNR1MAPTCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14370361 | 0.74 | MAPT (0.43) | CNR1MAPTCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| EP-2558099-A2 | KINASE INHIBITORS | The Regents Of The University Of California, San Francisco (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-0376590-B1 | Monomer or polymer composition derived from acryloxy alkyl cyanoacetamides | ROHM & HAAS (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5021511-A | Reacted with carbon-michael addition acceptor; coatings, adhesives, caulks, mastics; nonhydrolyzing | ROHM AND HAAS COMPANY (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0376590-A2 | Monomer or polymer composition derived from acryloxy alkyl cyanoacetamides | ROHM AND HAAS COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| US-3985763-A | DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035325-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | MCL1 416/4885CNR1 2917/4885CASP1 2662/4885 |
| US-20150045343-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | MCL1 416/4885CNR1 2917/4885CASP1 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.